Effect of US Drug Enforcement Administration’s Rescheduling of Hydrocodone Combination Analgesic Products on Opioid Analgesic Prescribing
Christopher M. Jones(Centers for Disease Control and Prevention), Douglas C. Throckmorton(United States Food and Drug Administration), Peter Lurie(United States Food and Drug Administration)
Cited by 127
Related Papers
Trends in US Emergency Department Visits for Mental Health, Overdose, and Violence Outcomes Before and During the COVID-19 Pandemic
|JAMA Psychiatry|2021|594
Drug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and Labeling
|Clinical Pharmacology & Therapeutics|2007|582
Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium
|Nature Biotechnology|2010|406
PDGF and TGF-β mediate collagen production by mesangial cells exposed to advanced glycosylation end products
|Kidney International|1995|174
Activation-induced apoptosis in human macrophages: developmental regulation of a novel cell death pathway by macrophage colony-stimulating factor and interferon gamma.
|The Journal of Experimental Medicine|1995|172